A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-Infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA

Trial Profile

A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-Infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2012

At a glance

  • Drugs Enfuvirtide (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2012 Actual end date (1 Jan 2010) added as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2007 Actual patient number is 18 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top